This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/wikipedia/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/pubchem-substance/
n18http://linked.opendata.cz/ontology/sukl/drug/
n19http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01107/identifier/kegg-drug/

Statements

Subject Item
n2:DB01107
rdf:type
n3:Drug
n3:description
Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990. [Wikipedia]
n3:generalReferences
# Contos DA, Dixon KF, Guthrie RM, Gerber N, Mays DC: Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration. J Pharm Sci. 1991 Aug;80(8):768-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1686463 # Gwilt PR, Pankaskie MC, Thornburg JE, Zustiak R, Shoenthal DR: Pharmacokinetics of methyprylon following a single oral dose. J Pharm Sci. 1985 Sep;74(9):1001-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2866242 # Lomen P, Linet OI: Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients. J Int Med Res. 1976;4(1):55-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16792
n3:group
illicit withdrawn approved
n3:halfLife
6-16 hours
n3:indication
For the treatment of insomnia.
owl:sameAs
n11:DB01107 n17:DB01107
dcterms:title
Methyprylon
adms:identifier
n6:4162 n7:DB01107 n8:D01150 n9:46506891 n12:PA164746748 n13:Methyprylon n20:4018
n3:mechanismOfAction
Methyprylon binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
n3:synonym
Metiprilon Methyprolon Methyprylonum Methyprylon Methprylon Noludar Metiprilona Metiprilone Methyprylone
n3:toxicity
Symptoms of overdose include excitation and convulsions.
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
60%
n15:hasConcept
n16:M0224669
n3:IUPAC-Name
n4:271B4073-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4079-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4078-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4075-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4076-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4077-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4089-363D-11E5-9242-09173F13E4C5 n4:271B4071-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B408A-363D-11E5-9242-09173F13E4C5 n4:271B4072-363D-11E5-9242-09173F13E4C5 n4:271B406F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4070-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:N05CE02
n3:H-Bond-Acceptor-Count
n4:271B407F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4080-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B407A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B407B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B407D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B407C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B407E-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
125-64-4
n3:category
n3:Bioavailability
n4:271B4085-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4087-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4088-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4084-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4083-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4086-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4074-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4081-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4082-363D-11E5-9242-09173F13E4C5